Key clinical point: Sequential chemoradiation improved disease-free survival when compared with concurrent chemoradiation or radiation alone after surgery for early-stage cervical cancer.
Major finding: In the intent-to-treat population, 3-year disease-free survival rates were 90% in patients randomized to sequential chemoradiation, 85% in patients randomized to concurrent chemoradiation, and 82% in patients randomized to radiation alone (hazard ratios, 0.52 for sequential chemoradiation vs. radiation alone and 0.65 for sequential vs. concurrent chemoradiation; P = .03).
Study details: A phase 3 study of 1,048 patients.
Disclosures: The study was sponsored by Sun Yat-sen University in collaboration with Guangdong Provincial People’s Hospital, First Affiliated Hospital/Sun Yat-Sen University, Shenzhen People’s Hospital, and Cancer Hospital of Guangxi Medical University. Dr. Huang reported receiving honoraria, travel, accommodations, and expenses from AstraZeneca.
Huang H et al. ASCO 2020, Abstract 6007.